Unknown PHASE4 INTERVENTIONAL 7-arm NCT02027337

Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives, Correction by Antioxidants

The Changes of Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives With Antiandrogenic Activity, Correction by Antioxidants

Sponsor: Tyumen State Medical Academy

Conditions Hyperandrogenism Menstrual Irregularities Polycystic Ovarian Syndrome

Interventions 20 mcg ethinylestradiol /3 mg drospirenone 20 mcg ethinylestradiol/3 mg drospirenone and Selmevit 30 mcg ethinylestradiol/3 mg drospirenone 30 mcg ethinylestradiol/3 mg drospirenone and Selmevit 35 mcg ethinylestradiol/2 mg cyproterone 35 mcg ethinylestradiol/2 mg cyproterone and Selmevit

Updated 6 times since 2017 Last updated: Nov 20, 2014 Started: Dec 31, 2013 Primary completion: Mar 31, 2015 Completion: Oct 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Hyperandrogenism and Menstrual Irregularities and is currently ongoing. Tyumen State Medical Academy leads this study, which shows 6 recorded versions since 2013 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE4
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE4
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE4

First recorded

Dec 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tyumen State Medical Academy

Data source: Tyumen State Medical Academy

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tyumen, Russia